Cas9 Protein Topical Treatment Blocks Corneal Neovascularization

Cas9 Protein Topical Treatment Blocks Corneal Neovascularization

In a groundbreaking advance that promises to revolutionize the treatment of corneal diseases, researchers have unveiled a novel, non-viral CRISPR/Cas9-based gene therapy that can be administered through topical eye drops to curb pathological corneal neovascularization. This breakthrough study, recently published in Gene Therapy, addresses a pressing clinical challenge by offering an effective, safe, and non-invasive therapeutic alternative to th…